Kao SC - Search Results

1

Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.

Kao SC, Yan TD, Lee K, Burn J, Henderson DW, Klebe S, Kennedy C, Vardy J, Clarke S, van Zandwijk N, McCaughan BC. Kao SC, et al. J Thorac Oncol. 2011 Mar;6(3):602-5. doi: 10.1097/JTO.0b013e31820ce2c7. J Thorac Oncol. 2011. PMID: 21266919 Free article.

2

A pathological complete response in malignant pleural mesothelioma after combination chemotherapy with Carboplatin and pemetrexed.

Kao SC, McCaughan B, Muljono A, Boyer M. Kao SC, et al. J Thorac Oncol. 2010 Mar;5(3):405-6. doi: 10.1097/JTO.0b013e3181c8cb16. J Thorac Oncol. 2010. PMID: 20186029 Free article. No abstract available.

3

Molecular biomarkers in malignant mesothelioma: state of the art.

Kao SC, Reid G, van Zandwijk N, Henderson DW, Klebe S. Kao SC, et al. Pathology. 2011 Apr;43(3):201-12. doi: 10.1097/PAT.0b013e3283445e67. Pathology. 2011. PMID: 21436629 Review.

4

Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma.

Kao SC, Griggs K, Lee K, Armstrong N, Clarke S, Vardy J, van Zandwijk N, Burn J, McCaughan BC, Henderson DW, Klebe S. Kao SC, et al. Pathology. 2011 Jun;43(4):313-7. doi: 10.1097/PAT.0b013e32834642da. Pathology. 2011. PMID: 21532523

5

The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N. Kao SC, et al. Lung Cancer. 2012 Feb;75(2):248-54. doi: 10.1016/j.lungcan.2011.06.007. Epub 2011 Jul 16. Lung Cancer. 2012. PMID: 21757252

6

The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.

Clarey J, Kao SC, Clarke SJ, Vardy J. Clarey J, et al. Among authors: kao sc. Ann Oncol. 2012 May;23(5):1229-1233. doi: 10.1093/annonc/mdr443. Epub 2011 Oct 10. Ann Oncol. 2012. PMID: 21986095 Free article.

7

Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.

Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B. Kao SC, et al. J Thorac Oncol. 2011 Nov;6(11):1923-9. doi: 10.1097/JTO.0b013e31822a3740. J Thorac Oncol. 2011. PMID: 22011651 Free article.

8

Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.

Kao SC, Armstrong N, Condon B, Griggs K, McCaughan B, Maltby S, Wilson A, Henderson DW, Klebe S. Kao SC, et al. Cancer. 2012 Jun 1;118(11):2952-61. doi: 10.1002/cncr.26497. Epub 2011 Oct 21. Cancer. 2012. PMID: 22020536 Free article.

9

Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.

Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. Kao SC, et al. Asia Pac J Clin Oncol. 2015 Mar;11(1):85-92. doi: 10.1111/ajco.12306. Epub 2014 Nov 10. Asia Pac J Clin Oncol. 2015. PMID: 25382807

10

Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.

McNamee N, Harvey C, Gray L, Khoo T, Lingam L, Zhang B, Nindra U, Yip PY, Pal A, Clay T, Arulananda S, Itchins M, Pavlakis N, Kao S, Bowyer S, Chin V, Warburton L, Pires da Silva I, John T, Solomon B, Alexander M, Nagrial A. McNamee N, et al. J Thorac Oncol. 2024 Apr;19(4):636-642. doi: 10.1016/j.jtho.2023.11.014. Epub 2023 Nov 28. J Thorac Oncol. 2024. PMID: 38036250

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

494 results

Search Page

Filters